| Drug Name | ***0115 |
| Description |
A nanoparticle albumin-bound docetaxel is in preclinical development for the treatment of solid tumors. |
| Target | Tubulin |
| Drug Modality | Nanoparticle |
| Indication | Solid Tumor |
| Product Category | Taxanes |
| Mechanism of Action | Inhibiting polymerization of tubulin to form microtubule |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |